TSE:4568Pharmaceuticals
FDA Priority Review For Ifinatamab Deruxtecan Might Change The Case For Investing In Daiichi Sankyo (TSE:4568)
In April 2026, Daiichi Sankyo and Merck reported that the FDA accepted and granted Priority Review to their Biologics License Application for ifinatamab deruxtecan for adults with extensive-stage small cell lung cancer progressing after platinum-based chemotherapy, with an FDA action date set for October 10, 2026.
This Priority Review, alongside Breakthrough Therapy Designation and inclusion in programs like Real-Time Oncology Review and Project Orbis, underscores regulatory momentum for...